Cue Biopharma earnings date
Want to see CUE full AI Analyst Report?
Cue Biopharma (CUE) Q2 2024 Earnings Report
CUE Q2 2024 EPS Results
- Actual EPS
- -$6.00
- Consensus EPS
- -$8.40
- Beat/Miss
- Beat by +$2.40
- One Year Ago EPS
- -$8.70
CUE Q2 2024 Revenue Results
- Actual Revenue
- $2.66M
- Expected Revenue
- $1.29M
- Beat/Miss
- Beat by +$1.37M
- YoY Revenue Growth
- +92.33%
Earnings Announcement Details
- Quarter
- Q2 2024
- Date
- 08/19/2024
- Time
- After Close
- Conference Call
- Monday, August 19, 2024
Cue Biopharma's next earnings date is estimated for March 23, 2027, based on past reporting schedules.
Q2 2024 Earnings Call Audio
Q2 2024 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2024 Earnings Call Summary
The call presented several positive developments in clinical trials and strategic financial management, but also noted delays in trial launches and competitive market challenges.
During Cue Biopharma's Q2 2024 earnings call, the executives provided guidance on several metrics and strategic priorities. They highlighted their focus on reducing capital requirements by achieving a cash burn reduction from $40 million to $30 million annually, extending their runway to mid-2025. The company is advancing its CUE-101 and CUE-102 oncology programs, with CUE-101 showing an objective response rate of 46% and a notable 12-month overall survival rate of 90% in a combination trial with pembrolizumab. Cue-401, in collaboration with ONO Pharmaceuticals, targets autoimmune diseases, with lead candidate selection anticipated in Q1 2025. Additionally, CUE-501 is being positioned for strategic partnering, aimed at addressing B-cell-mediated autoimmune diseases. The company's approach includes leveraging strategic partnerships to optimize resource allocation and bolster cash flow through milestone payments and potential co-development agreements.
- CUE-101 and Pembrolizumab Combination Shows Promising ResultsCUE-101 in combination with Pembrolizumab shows an objective response rate (ORR) of 46% in patients with CPS ≥ 1, compared to the historical ORR of 19% with Pembrolizumab alone. The 12-month overall survival (OS) is 90% with a median OS of 21.8 months.
- Strong Performance in Low CPS Score PatientsPatients with low CPS scores (1 to 19) showed an ORR of 50% with CUE-101 and Pembrolizumab, significantly higher than the historical 15% with Pembrolizumab alone.
- CUE-401 Autoimmune Program ProgressCUE-401, in collaboration with ONO Pharmaceuticals, shows promising data in generating regulatory T cells and is moving towards lead candidate selection in Q1 2025.
- Financial Strategy and Extended RunwayThrough strategic measures, the company's runway is extended to mid-2025 while reducing annual cash burn from $40 million to $30 million.
CUE Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 23, 2027 | 2026 (Q4) | -1.76- | 0.3 | ― | ― |
| Nov 16, 2026 | 2026 (Q3) | -2.24-4.74 | -2.1 | -125.71% (-2.64) | |
| Aug 17, 2026 | 2026 (Q2) | -1.69-24.14 | -2.7 | -794.07% (-21.44) | |
| May 14, 2026 | 2026 (Q1) | ―-1.08 | -5.1 | 78.82% (+4.02) | |
| Mar 16, 2026 | 2025 (Q4) | -2.700.30 | -3.9 | 107.69% (+4.20) | |
| Nov 12, 2025 | 2025 (Q3) | -2.80-2.10 | -5.1 | 58.82% (+3.00) | |
| Aug 12, 2025 | 2025 (Q2) | -3.90-2.70 | -6 | 55.00% (+3.30) | |
| May 12, 2025 | 2025 (Q1) | ―-0.17 | -7.5 | 97.73% (+7.33) | |
| Mar 31, 2025 | 2024 (Q4) | -4.60-5.10 | -7.5 | 32.00% (+2.40) | |
| Nov 14, 2024 | 2024 (Q3) | -5.47-5.10 | -7.2 | 29.17% (+2.10) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

